Disease-A-Month
Volume 54, Issue 7 , Pages 432-444 , July 2008

Hepatocellular Carcinoma

References 

  1. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007;110:2119–2152
  2. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–1014
  3. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16
  4. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–S50
  5. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16
  6. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant. 2003;9:331–338
  7. Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4:432–441
  8. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121
  9. El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–468
  10. Yuan JM, Govindarajan S, Arakawa K, et al. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.. Cancer. 2004;101:1009–1017
  11. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127:S79–S86
  12. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus (A prospective study of 22 707 men in Taiwan). Lancet. 1981;2:1129–1133
  13. Sakuma K, Saitoh N, Kasai M, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology. 1988;8:1642–1646
  14. McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae (Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers). Arch Intern Med. 1990;150:1051–1054
  15. El Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160:3227–3230
  16. El Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37(suppl 2):S88–S94
  17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  18. Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology. 2006;43:S145–S150
  19. Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006;44:798–805
  20. El Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158–166
  21. Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg. 1995;169:28–34
  22. Lang BH, Poon RT, Fan ST, et al. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol. 2004;99:2158–2165
  23. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422
  24. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  25. Ishiguchi T, Shimamoto K, Fukatsu H, et al. Radiologic diagnosis of hepatocellular carcinoma. Semin Surg Oncol. 1996;12:164–169
  26. Dodd RL, Baron JH, Oliver GD, et al. Spectrum of imaging findings of the liver in end-stage cirrhosis: part I, gross morphology and diffuse abnormalities. AJR Am J Roentgenol. 1999;173:1031–1036
  27. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2007;47:97–104
  28. Larcos G, Sorokopud H, Berry G, et al. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol. 1998;171:433–435
  29. Xu HX, Xie XY, Lu MD, et al. Contrast-enhanced sonography in the diagnosis of small hepatocellular carcinoma ≤2 cm. J Clin Ultrasound. 2008;36:257–266
  30. Kuo PH, Kanal E, Abu-Alfa AK, et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647–649
  31. Lencioni R, Mascalchi M, Caramella D, et al. Small hepatocellular carcinoma: differentiation from adenomatous hyperplasia with color doppler ultrasound and dynamic Gd-DTPA enhanced MR imaging. Abdom Imaging. 1996;21:41–48
  32. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38:1034–1042
  33. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2007;47:97–104
  34. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707–716
  35. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma (The Cancer of the Liver Italian Program (CLIP) Investigators). Hepatology. 2000;31:840–845
  36. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338
  37. Huo TI, Lin HC, Hsia CY, et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol. 2007;102:1920–1930
  38. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111:1018–1022
  39. Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998;28:1241–1246
  40. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111:1018–1022
  41. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999;353:797–801
  42. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma (Hepatoma Prevention Study Group). N Engl J Med. 1996;334:1561–1567
  43. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrohosis. N Engl J Med. 1996;334:693–699
  44. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology. 1998;27:1572–1577
  45. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transplant. 2002;8:873–883
  46. Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210:655–661
  47. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000;214:761–768
  48. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171
  49. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739

PII: S0011-5029(08)00040-0

doi: 10.1016/j.disamonth.2008.03.005

Disease-A-Month
Volume 54, Issue 7 , Pages 432-444 , July 2008

Article Tools